Related Experiment Video

Updated: Jul 14, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

[Cystic fibrosis and pseudomonas aeruginosa current and future strategies]

A Leonard1, T Leal, P Lebecque

  • 1Service de pédiatrie générale, Cliniques Universitaires Saint-Luc, Universit6éCatholique de Louvain, Brussels, Belgium. Lebecque@pedi.ucl.ac.be

Journal De Pharmacie De Belgique
|May 19, 2007
PubMed

Insights

Preventing Pseudomonas aeruginosa lung infections is crucial for cystic fibrosis (CF) patients. Future strategies may include vaccines and prophylactic inhaled antibiotics to combat this persistent pathogen.

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Microbiology

Context:

  • Pseudomonas aeruginosa is the primary pathogen in cystic fibrosis (CF) lung infections.
  • Preventing or delaying chronic colonization by P. aeruginosa is a major clinical challenge in CF care.
  • Current early intervention strategies have a significant failure rate (around 20%).

Purpose:

  • To review current and explore future strategies for managing P. aeruginosa in cystic fibrosis.
  • To highlight the need for novel approaches beyond early intervention, such as vaccines and prophylaxis.
  • To discuss the role of inhaled and intravenous antibiotics in both early and chronic colonization phases.

Summary:

  • Early intervention to prevent P. aeruginosa colonization in CF patients is critical but has limitations.
  • Vaccine development and prophylactic inhaled antibiotics represent promising future strategies.
  • In chronically colonized patients, inhaled antibiotics and oral azithromycin slow disease progression.
  • The optimal use of intravenous antibiotics in chronic P. aeruginosa infection remains debated.

Impact:

  • This review informs clinical practice by evaluating existing and emerging P. aeruginosa management strategies in CF.
  • It emphasizes the potential of prophylactic and therapeutic antibiotic use, alongside vaccine development.
  • Findings guide future research directions for improving outcomes in cystic fibrosis patients.

More Related Videos

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Gene Regulation in Microbial Communities: Quorum Sensing01:28

Gene Regulation in Microbial Communities: Quorum Sensing

Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: